Hypophosphatemic Rickets Clinical Trial
Official title:
Milk Products in the Treatment of Hypophosphatemic Rickets: A Randomised Crossover Trial
Verified date | October 2017 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study was to investigate the feasibility and efficacy of a high intake of milk and/or cheese products compared to phosphate tablets in patients with hypophosphatemic rickets when evaluating the S-phosphate levels as a main effect parameter. The study was designed as a randomized, multiple crossover study.
Status | Completed |
Enrollment | 7 |
Est. completion date | June 1, 2016 |
Est. primary completion date | June 1, 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 14 Years and older |
Eligibility |
Inclusion Criteria: - Genetic verified hypophosphatemic rickets. - In treated with oral phosphate tablets. Exclusion Criteria: - Tertiary hyperparathydoism. - In treatment with Cinacalcet. - Suffered from milk allergy. |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital, Skejby | Aarhus N |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus | Aarhus University Hospital, Kolding Sygehus, University of East Anglia |
Denmark,
Bastepe M, Jüppner H. Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord. 2008 Jun;9(2):171-80. doi: 10.1007/s11154-008-9075-3. Epub 2008 Mar 26. Review. — View Citation
Beck-Nielsen SS, Brixen K, Gram J, Brusgaard K. Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets. J Hum Genet. 2012 Jul;57(7):453-8. doi: 10.1038/jhg.2012.56. Epub 2012 Jun 14. — View Citation
Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol. 2009 Mar;160(3):491-7. doi: 10.1530/EJE-08-0818. Epub 2008 Dec 18. — View Citation
Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, Frappier D, Burkett K, Carpenter TO, Anderson D, Garabedian M, Sermet I, Fujiwara TM, Morgan K, Tenenhouse HS, Juppner H. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet. 2006 Feb;78(2):179-92. Epub 2005 Dec 9. — View Citation
Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res. 2011 Jul;26(7):1381-8. doi: 10.1002/jbmr.340. Epub 2011 May 2. Review. Erratum in: J Bone Miner Res. 2015 Feb;30(2):394. — View Citation
Karp HJ, Vaihia KP, Kärkkäinen MU, Niemistö MJ, Lamberg-Allardt CJ. Acute effects of different phosphorus sources on calcium and bone metabolism in young women: a whole-foods approach. Calcif Tissue Int. 2007 Apr;80(4):251-8. Epub 2007 Apr 1. — View Citation
Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella SH, Collins MT. Tumour-induced osteomalacia. Nat Rev Dis Primers. 2017 Jul 13;3:17044. doi: 10.1038/nrdp.2017.44. Review. — View Citation
Nielsen LH, Rahbek ET, Beck-Nielsen SS, Christesen HT. Treatment of hypophosphataemic rickets in children remains a challenge. Dan Med J. 2014 Jul;61(7):A4874. — View Citation
Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009 Dec;94(12):4860-7. doi: 10.1210/jc.2009-1472. Epub 2009 Oct 16. — View Citation
Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto K, Fukushima N. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem. 2003 Jan 24;278(4):2206-11. Epub 2002 Nov 4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum phosphate. | Evaluated in blood samples. Evaluated after three days of treatment, where we collected blood 5 times through out one day. | Three days. | |
Secondary | Fibroblast growth factor 23. | Evaluated in blood samples. Evaluated after three days of treatment, where we collected blood 5 times through out one day. | Three days. | |
Secondary | Parathyroid hormone. | Evaluated in blood samples. Evaluated after three days of treatment, where we collected blood 5 times through out one day. | Three days. | |
Secondary | Total calcium. | Evaluated in blood samples. Evaluated after three days of treatment, where we collected blood 5 times through out one day. | Three days. | |
Secondary | Basic phosphatase. | Evaluated in blood samples. Evaluated after three days of treatment, where we collected blood 5 times through out one day. | Three days. | |
Secondary | Urine phosphate. | Evaluated in urine samples. Urine samples for phosphate was collected in containers from 0800 to 1200 and from 1200 to 1600. A 24-hour urine samples was obtained from the day before the sampling from 0800 to 0800 hours the following morning. | One day. | |
Secondary | Urine calcium. | Evaluated in urine samples. Urine samples for calcium was collected in containers from 0800 to 1200 and from 1200 to 1600. A 24-hour urine samples was obtained from the day before the sampling from 0800 to 0800 hours the following morning. | One day. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03748966 -
Calcitriol Monotherapy for X-Linked Hypophosphatemia
|
Early Phase 1 | |
Active, not recruiting |
NCT03651505 -
X-linked Hypophosphatemia Disease Monitoring Program
|
||
Completed |
NCT03581591 -
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
|
Phase 3 | |
Completed |
NCT04184661 -
Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts
|
||
Active, not recruiting |
NCT00473187 -
Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets
|
Phase 1 |